Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

7.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

6.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.7K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomonitoring arsenic exposure by ancestry: the healthy life in an urban setting (HELIUS) study.

Regulatory toxicology and pharmacology : RTP·2025
Same author

Exercise and hypoxia independently stimulate platelet liberation of brain-derived neurotrophic factor and platelet factor 4.

The Journal of physiology·2025
Same author

Creatine Kinase and New-Onset Hypertension: A 10-Year Follow-Up Study.

American journal of hypertension·2025
Same author

Exosomes in ultrastructural resistance artery remodeling of human hypertension.

Ultrastructural pathology·2025
Same author

Losartan and Microvascular Reactivity in Women with a History of Preeclampsia.

American journal of hypertension·2025
Same author

Ultrastructural changes in resistance arterioles of normotensive and hypertensive premenopausal women with uterine fibroids.

Ultrastructural pathology·2023

Related Experiment Video

Updated: Apr 22, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.3K

Creatine kinase inhibits ADP-induced platelet aggregation.

D L Horjus1, R Nieuwland2, K B Boateng1

  • 1Dept. of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Scientific Reports
|October 10, 2014
PubMed
Summary

Plasma creatine kinase levels influence bleeding risk by inhibiting platelet activation. Higher enzyme levels reduce platelet aggregation, potentially increasing bleeding, especially with antiplatelet drugs targeting ADP receptors.

More Related Videos

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

21.5K
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

916

Related Experiment Videos

Last Updated: Apr 22, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.3K
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

21.5K
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

916

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Bleeding risk associated with antiplatelet therapy presents a significant clinical challenge.
  • Inter-individual variability in bleeding risk is not well understood.
  • Platelet activation, particularly via adenosine diphosphate (ADP), is a key factor in thrombosis and bleeding.

Purpose of the Study:

  • To investigate whether plasma creatine kinase levels modulate bleeding risk.
  • To determine if creatine kinase inhibits ADP-induced platelet activation in a dose-dependent manner.

Main Methods:

  • In vitro experiments adding exogenous creatine kinase to human plasma.
  • Measurement of ADP-induced platelet aggregation.
  • In vivo study of endogenous plasma creatine kinase levels and platelet aggregation in healthy men, including post-exercise assessment.

Main Results:

  • Exogenous creatine kinase dose-dependently inhibited ADP-induced platelet aggregation in human plasma.
  • Endogenous plasma creatine kinase levels in healthy men correlated inversely with ADP-induced platelet aggregation.
  • Significantly reduced platelet aggregation was observed at very high creatine kinase levels post-exercise, normalizing as levels decreased.

Conclusions:

  • Creatine kinase reduces ADP-induced platelet activation.
  • This enzymatic activity may contribute to bleeding risk, particularly in patients using P2Y12 receptor inhibitors.